ReviewCurrent drug targets2025
New Advances in Drug Research for Myopia Control in Adolescents.
Review in Current drug targets, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Management of myopia: a mini-review.Medical hypothesis, discovery & innovation ophthalmology journal · 2026Review
- Myopia development: multifactorial interplay, molecular mechanisms and possible strategies.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMyopia is one of the most common eye diseases worldwide, with an increasing incidence observed in recent years. Globally, effective treatments for myopia have been extensively explored. In recent years, research on drugs for the treatment of myopia has become a popular topic in ophthalmology, with some breakthroughs having been achieved. Compared with surgical treatment, drug treatment is easier for people to accept. Although the efficacy of some drugs in delaying the development of myopia has been confirmed, the mechanism and site of action of some drugs are still not completely clear.
objectiveIn this study, we review the recent related research on drug therapy for myopia at home and abroad, describe the mechanism of various drugs in treating myopia, evaluate their clinical application value, and identify existing problems.
resultsThese drugs include atropine, a series of anticholinergic drugs, dopamine agonists, 7- methylxanthine, and intraocular pressure-lowering drugs.
conclusionResults highlight the efficacy of atropine in myopia treatment with minimal side effects. Anticholinergic medications, such as atropine, have demonstrated efficacy in managing the progression of myopia with a reduced incidence of adverse effects. The emphasis is placed on achieving better long-term effectiveness and minimizing the rebound effect after treatment is stopped. Furthermore, participating in outdoor activities and reducing eye strain are proven strategies for preventing myopia.
Indexed as
Identifiers
39838677What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.